Pfizer (NYSE:PFE) Stock Price Up 0.4% - What's Next?

Pfizer Inc. (NYSE:PFE - Get Free Report) shares rose 0.4% during trading on Friday . The company traded as high as $24.30 and last traded at $24.02. Approximately 11,108,670 shares changed hands during trading, a decline of 77% from the average daily volume of 48,093,734 shares. The stock had previously closed at $23.93.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Price Performance

The stock has a market cap of $137.19 billion, a price-to-earnings ratio of 17.16, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a 50 day simple moving average of $24.34 and a 200-day simple moving average of $25.78. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.82 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.11%. Pfizer's payout ratio is currently 124.64%.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company's stock.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the fourth quarter valued at $28,000. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.